Evaluation of potential biomarkers for lenvatinib plus pembrolizumab among patients with advanced endometrial cancer: results from Study 111/KEYNOTE-146

Vicky Makker; Matthew H Taylor; Carol Aghajanian; Allen L Cohn; Marcia S Brose; Christopher Di Simone; Zhu Alexander Cao; Leah Suttner; Andrey Loboda; Razvan Cristescu; Petar Jelinic; Robert Orlowski; Lea Dutta; Junji Matsui; Corina E Dutcus; Yukinori Minoshima; Mark J Messing

doi:10.1136/jitc-2023-007929

Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Browse by collection

Archive

Authors

About
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Alerts

PDF

Clinical/translational cancer immunotherapy

Original research

Evaluation of potential biomarkers for lenvatinib plus pembrolizumab among patients with advanced endometrial cancer: results from Study 111/KEYNOTE-146

Log in using your username and password

Main menu

Log in using your username and password

You are here

Read the full text or download the PDF:

Log in using your username and password